PM Modi inaugurates Lyfius Pharma Penicillin-G Facility in AP

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-10-30T11:13:04+05:30 | Updated On 30 Oct 2024 11:13 AM IST

Kakinada: Lyfius Pharma, a wholly owned step-down subsidiary of Aurobindo Pharma has announced the inauguration of its state-of-the-art PenG manufacturing facility, at Kakinada, Andhra Pradesh. With an annual production capacity of 15,000 metric tonnes (MT), the facility was virtually inaugurated by Hon’ble Prime Minister Shri. Narendra Modi in the presence of Jagat Prakash Nadda (Union Minister of Chemicals & Fertilizers, Health & Family Welfare), Dr. Mansukh Mandaviya (Union Minister of Labour & Employment, Youth Affairs & Sports), Smt. Anupriya Patel (Union MoS Chemicals & Fertilizers, Health & Family Welfare), Shri. Prataprao Jadhav (Union MoS (IC) Ayush, MoS Health & Family Welfare) and Sushri Shobha Karandlaje (Union MoS Labour & Employment, Micro, Small & Medium Enterprises).

This facility represents a strategic investment of ₹2,500 crores, under the Government of India’s PLI Scheme, and exemplifies how private sector participation can significantly contribute to national growth, drive innovation, and enhance healthcare security.

The PLI scheme for the pharmaceutical sector aims to strengthen domestic manufacturing capabilities in critical KSMs, DIs, and APIs.

Commenting on the occasion, Mr. M.V. Rama Krishna, Director Lyfius Pharma, said “The launch of our PenG facility is a significant milestone in our efforts to enhance local production and reduce import dependency for critical pharmaceutical ingredients. This investment underscores our commitment to support the government’s vision of ‘Atmanirbhar Bharat’, establishing India as a global pharmaceutical manufacturing hub.”

Lyfius Pharma is engaged in the manufacturing of Penicillin-G. Its state-of-art facility is situated at Kakinada, Andhra Pradesh, approved under the PLI (Production Linked Incentive) scheme.

Lyfius PharmaPenGPM narendra modiaurobindo pharma

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751